Life Sciences Archive » March, 2020

Life Sciences - March, 2020

445 articles

• Teva Can't Nix ERISA Suit Over Excessive Fee Allegations
• How COVID-19 Could Spur The Gov't To Seize Patents
• Avet Diabetes Med Contains Carcinogen, Suit Says
• Allergan Defeats Untimely NJ Insurance Fraud Claims
• Indivior Again Fails To Dodge Feds' Opioid Marketing Case
• Gov't Contracts Of The Month: Virus, Wall, Missile Defense
• EpiPen Buyers Can't Inject RICO Suit Into MDL, Court Told
• Ex-Theranos CEO Wants Trial Prep OK'd Amid Pandemic
• Law Firm Pay Cuts, Layoffs Will Likely Multiply
• Amarin's Vascepa Patents Struck Down As Generics Ramp Up
• 9th Circ. Lifts Stay In Soured IVF Center Deal Dispute
• Atty Says Stock Fraud Conviction Based On False Testimony
• Key Takeaways From DOJ's 2019 FCA Recovery Stats
• What FDA Has Done So Far In Response To COVID-19
• FDA Seeks Extension Of Vape App Deadline Due To COVID-19
• Evoqua Must Face Some Investor Claims Over $500M IPO
• 3 Steps To Building Effective Teams While On Lockdown
• Merck Can't Trim Dozens Of Suits From Zostavax MDL
• Health Hires: Arnold & Porter, Winston & Strawn, Ice Miller
• Ra Pharma's $2.1B Sale Teed Up To Close After False Starts
• Genentech Loses Eye-Drug Patent Rights Over Agent's Error
• Cadwalader Cuts Pay Across The Firm To Weather Pandemic
• Tucker Ellis Adds Bankruptcy Partner In Chicago
• Fed. Circ. Won't Stay Arthrex Decision For High Court Appeal
• White House Expects Huge Death Toll As Virus Rages On
• Businesses Urged To Make COVID-19 IP Free During Crisis
• Sen. Floats Bill To Shield COVID-19 Doctors From Legal Action
• 6th Circ. Says Court Had No Jurisdiction In DePuy Hip Suit
• Monsanto Wants To Erase $265M Dicamba Verdict
• CBD Buyers Say They Shouldn't Have To Wait For FDA Action
• Bluebird Bio Directors 'Grossly' Overpaid, Chancery Suit Says
• Anapol Weiss Seeks Much Of $3.8M Sorin MDL Common Fund
• Texas Cos. Look To Block ACA Preventive-Care Mandates
• FTC Fights Surescripts' Bid For DC Circuit Appeal
• Companies Forced To Get Creative As Public Markets Stall
• Some Claims Weeded Out Of CBD False Ad Suit
• Del. Court Says DuPont Can Arbitrate Chemours Suit
• Latham Steers Cancer Therapy Biz In $130M IPO Filing
• US Trustee Says Melinta Plan Releases Go Too Far
• Tips For Cos. Confronting Pandemic Impact On Global Trade
• EU Trade Chief Defends Medical Export Restrictions
• High Court Won't Revive Enzo Suit Over 'Lax' Enablement Test
• Law Firm Mergers Dry Up Due To Coronavirus Pandemic
• Client Advocacy Tips For Remote Hearings During COVID-19
• How To Conduct Depositions Remotely
• Potential Cancer Drugs Licensed In Deal Worth Up To $137M
• COVID-19 Raises Unique Issues For Health, Life Sciences Cos.
• The Attys And Legal Logic Behind Stay-At-Home Orders
• Jushi Can't Stop Harvest's Acquisition Of Fla. Medical Pot Co.
• HHS Can't Appeal True Health Medicare Reimbursement Order
• Insurers Tell Justices Fed. Circ. Rule Will Keep Drug Prices Up
• CBD Co. Can't Shake Topical Cream Maker's Trade Secret Suit
• Lab Demands DOJ Reveal 'Secret' Cannabis Research Policy
• Trump Wields Wartime Law For GM To Make Ventilators
• All Arthrex Parties Back Feds' Stay Bid For High Court Appeal
• A Guide To Zealously Representing Clients During COVID-19
• Intercept Beats Investor Suit Over Liver Disease Drug Deaths
• Pfizer Wins Delay For Expert Busy On Coronavirus Task Force
• States Give Hemp Farmers A New Market In Marijuana Industry
• Coronavirus Q&A: Buchanan Ingersoll's FDA Chair
• Army Correct To Reject Bids From 2 Cos. With Same CEO
• Drug Pricing Legislation In Doubt After COVID-19 Relief Bill
• Fed. Circ. Affirms PTAB Ax Of 2 Cancer Drug Patents
• Meningitis Vaccine Developer Lands $110M In Funding Round
• Genentech Says It Shouldn't Lose Patent Rights Over Error
• Pandemic Won't Stop Arguments In J&J's $4.7B Talc Appeal
• NY AG Warns Air Purifier Sellers To Stop COVID-19 Claims
• G-20 Pledges Only Limited Trade Restrictions Amid COVID-19
• UK Watchdog Probes Elanco's Dog Ear Treatment Deal
• 3rd Circ. Won't Revive Merck Vaccine Suit Over Atty Conduct
• CBP Drops Plan To Delay Tariff Payment During COVID-19
• Trade Group Urges High Court To Bury Arkansas PBM Law
• Convicted Insys Exec Says Forfeiture Unfair In Bear Market
• Abbott Wins Test Strip Suit After Supplier's Discovery Fraud
• AGs Ask Feds To Allow Fetal Tissue Research For COVID-19
• Israel's Generic COVID-19 Drug Licensing Lacks Due Process
• Pandemic Spotlights Opportunistic Product Health Claims
• 7 Ways Attys Can Create The Right Home Office Environment
• Ariad Exec's Spouse Can't Shake Insider Trading Conviction
• After Backlash, Gilead Ditches 'Orphan' Status For Virus Drug
• Fed. Circ. Trims Galderma's Patent Win Over Oracea Generic
• Automakers' Shift To Med Supplies Comes With Legal Hazards
• D.C. Latest to Declare Medical Pot Essential In Outbreak
• Insurer Says No Coverage In Contaminated Melatonin Suit
• Ex-Pot Co. Exec to Mediate Fight Over Acquisition Cash
• Bayer And Novartis Lose Challenge To NHS Eye Drug Policy
• EU Probing J&J's $400M Deal For Takeda's Surgical Patch
• 10 E-Discovery Challenges Caused By COVID-19
• Data Co. Beats PBM's Suit Alleging Foreign Trade Secret Theft
• Jefferies Adds $10M To Federal Drug Packaging Partnership
• Abiomed Escapes FCA Whistleblower's Retaliation Claim
• Trump's Tariff Delay Proposal Draws Fire From US Producers
• Novartis Wants Lupin's Generic Heart Failure Drug Blocked
• COVID-19 As A Material Adverse Change In M&A Agreements
• NJ, Texas Law Firms Beat Suit Over Pelvic Mesh Atty Fees
• Express Scripts Off The Hook For $50M Prescription Drug Bill
• Counsel To Get Up To $93M In Fees In Xarelto MDL
• Chinese Cancer Research Co. Lands $60M Funding
• PTAB Sets More Precedent On Its Discretion To Deny Petitions
• Medical Pot Grower Can't Escape Ex-Partners' Suit
• Class Attys Seek More Than $4M For NantHealth IPO Action
• Fla. AG Targets 43 Vendors For Amazon Price-Gouging Claims
• Boehringer Beats Marketing Software Co. In Conspiracy Trial
• Trade Monitor Urges Lowering Barriers To Aid Virus Response
• Ex-Army Biomedical Engineer Can't Sink Philips NDA Suit
• EpiPen Buyers Tear Into Mylan, Pfizer Bid For Cert. Review
• BigLaw Leaders Must Prepare For COVID-19 Economic Fallout
• Maynard Cooper Nabs IP Litigator From Jones Day
• Edwards' Patent Suit Over Heart Valve Device Set For July Trial
• FEMA To Use Wartime Law To Meet COVID-19 Medical Demand
• Gibson Dunn Nabs Life Sciences Deals Atty From Goodwin
• Walgreens 'Systemically Overcharged' For Drugs, Insurers Say
• CBD Website Escapes Libel Suit Over 'Heavy Metals' Article
• Chinese Hospital Seeks Info On Soured IVF Center Deal
• Justices, Congress Might Tackle PTAB Constitutionality Next
• Opioid Negotiation Class Says It's Not Bound By 'Straitjacket'
• Orthodontist Assoc. Denied Amicus In SmileDirect Suit
• Mallinckrodt Dodges MS Drug Monopoly Suit
• Kappos Says Pandemic Calls For New Medical IP Precedent
• Drug Cos. Want Slow SF Opioid Case Timeline Amid COVID-19
• High Court Turns Down Allergan Breast Implant Suit
• Ex-Theranos Execs Holmes, Balwani To Get Separate Trials
• Open Issues After Fed. Circ. PTAB Judge Appointments Ruling
• Alnylam Dodges Stock-Drop Suit Over FDA Approval Efforts
• Ex-Pharma Exec Seeks Early Prison Exit Over COVID-19 Risk
• 3 Ways Leaders Can Improve Remote Work For Lawyers
• Tips For Online Mediation In The Age Of Social Distancing
• How To Manage Marketing Risks For CBD Products
• Mitsubishi, Janssen Seek To Block Generic Diabetes Drug
• 4 Cases Show Growing Reach Of Federal Fraud Statutes
• Pa. Relaxes Medical Pot Regs Amid Coronavirus Pandemic
• Drug Cos. Say 'Buy US' Order Would Hurt COVID-19 Response
• FTC Data Security Consent Orders Are New But Not Improved
• Ex-USPTO Leader, Oblon Attorney Mossinghoff Dies At 84
• USTR Flooded With Bids For COVID-19 Tariff Waivers
• Full Fed. Circ. Won't Review PTAB Unconstitutionality Case
• A Look Into FTC's Thinking On Pyramid Scheme Potential
• In Faultily Redacted Docs, Attys Say Exec Defrauded CBD Co.
• USTR Weighing China Tariff Cuts To Fight Coronavirus
• Insys Founder Tells 1st Circ. COVID-19 Risk Merits Bail
• Flintstones 'Complete' Vitamins Consumers Seek Class Cert.
• Market Turmoil Begins To Strain Even Blank-Check Deals
• Shkreli-Founded Co. Defends Its Handling Of Life-Saving Drug
• Real Estate Rumors: Deerfield, CGI, National Development
• DEA Pushes Major Increase Of Research Cannabis Cultivation
• Farming, Food Groups Sue EPA Over Glyphosate Approval
• 3 Firms Steer Chinese Pharma Co.'s $288M Hong Kong IPO
• J&J Says Talc Supplier Imerys Doesn't Need More Ch. 11 Time
• Ex-Pfizer Exec Fights Fidelity's Bid To Exit Pension Tax Suit
• Updating Publicly Traded Company Disclosures For COVID-19
• 3D Printing As Indirect Patent Infringement Amid COVID-19
• PTAB Axes Bulk Of Possible Cancer Treatment Patent In PGR
• FDA Tries To Boost Hand Sanitizers Amid COVID-19 Crisis
• Calif. Pay-For-Delay Ban Hurts Pharma Cos., 9th Circ. Told
• How Trump's Wartime Order Affects Medical Manufacturers
• 'Complete Disregard' Of Service Rules Kills Syneos Stock Suit
• Coronavirus-Disrupted Drug Firm's $23M Ch. 11 Sale OK'd
• Genentech Sues Fresenius Kabi Over Generic Cancer Drug
• Japanese Device Co. Must Face FCA Suit Over Medicare Fraud
• PTAB To Review Allergen Juvederm Patent At Heart Of IP Suit
• Nevada Says Pot Shops Can Stay Open Amid COVID-19 Crisis
• Judge Can't Impose Vape Application Deadline, 4th Circ. Told
• Danaher Gets FTC Approval For $21B GE Biopharma Deal
• SEC Settles PetMed Insider Trading Claims For $1.25M
• SmileDirect Complaint Against Calif. Dental Board Trimmed
• FDA Clears Abbott Test For COVID-19
• Mylan, Pfizer Want EpiPen Row Paused For Class Cert. Appeal
• US Trustee's Objections To Valeritas Settlement Resolved
• Investor Says Biotech Co. Blew Drug Approval, Hurting Stocks
• The Rising COVID-19 Bankruptcy Risks
• Ruling In HHS Case May Mean More Drug Trial Reporting
• Israel Defies AbbVie IP To Import Generic Drugs For COVID-19
• WTO Forms Panel To Hear EU-Turkey Drug Production Case
• Trump Races To Boost Health Capacity As Virus Cases Soar
• Judge Won't Pause Investors' Doc Bid For Chinese IVF Fight
• Biogen Sues Over 'Copycat' Alzheimer Treatment Products
• Md. Pot Shops Told To Stop Using 'Sniff Jars' Amid Outbreak
• Sens. Sound Privacy Alarm On Google's Virus Screening Site
• 'Pharma Bro' Suit Proceeds By Phone As COVID-19 Spreads
• Robins Kaplan To Share $2.2M Fee With NJ Solo Atty
• COVID-19 Closures Could Help Illegal Dealers, Pot Groups Say
• Gilead Knowingly Peddled Dangerous HIV Drugs, Suit Says
• Teva Warns Fed. Circ. IP Ruling Has 'Perverse Consequences'
• Purdue, Sacklers Keep Opioid Suit Shield For 6 More Months
• Bayer Asks Ill. Justices To Boot 160 Claims From Essure Suits
• COVID-19 Relief Bill Includes Protections For Face Masks
• First Zofran Bellwether Delayed Indefinitely Due To COVID-19
• Cell And Gene Therapies Are Driving M&A Deal Activity
• FTC Staffers Greenlight Allergan Divestitures In AbbVie Deal
• 7th Circ. Says Judge Wrongly Denied Disability Benefits
• LibbyHoopes Atty's Threat To Priest In SEC Case Irks Judge
• A Work-From-Home Tech Checklist For Law Firms
• Workers Call DST Bid To Boot ERISA Counsel A Delay Tactic
• NECC Execs Push 'Legal Impossibility' Defense In 1st Circ.
• Del. Jurors Clear Oxford Nanopore In DNA Tech Patent Suit
• NY County Fights Mallinckrodt Bid For Separate Opioid Trial
• The Top Coronavirus Questions Health Attys Are Hearing
• Split Fed. Circ. Revives Sequenom Fetal DNA Test Patents
• Medical Pot Deemed 'Essential' Amid COVID-19 Shutdowns
• CBD Producer Wants Out Of Suit Alleging Illegal Product Sales
• Del. Justices Say Partner Swap Kills Whistleblower Standing
• Indivior Rips New Filings In 3rd Circ. Suboxone Antitrust Row
• Glancy Prongay Seeks To Represent Blood Clot Co. Investors
• Feds Say Greenberg Traurig Has Conflict In $1B Fraud Case
• Doc Who Pled Guilty To Pushing Pill 'Goodie Bags' To Pay $3M
• Major Cos. Urge Justices To Hear Generics Discovery Row
• DNA Registry, Sperm Bank Intersection Raises Legal Issues
• Fortress Offers IP Rights To Fight COVID-19 After Backlash
• Venture-Backed Biotech Firm Files $86M IPO In Stalled Market
• SEC Says Fla. Men Traded On PetMed Insider Info
• Risperdal Breast-Growth Trial Won't Go To Pa. Supreme Court
• FDA Finalizes New Cigarette Warning Graphics After Setbacks
• 7 Keys To Keeping Your Firm Inclusive In The Coronavirus Era
• China's Review Of Vertical Mergers Is Instructive For US
• 3 Firms Steer BioPharma's Go-Public With Blank Check Co.
• AGC Launches €240M Offer For Italian Biotech Molmed
• FDA Offers 'Unprecedented' Leeway For Coronavirus Tests
• Class Cert. Extended In Monsanto, BASF Dicamba MDL
• Hemp Co. Says CBD Wares Not 'Illegal,' Just Not Regulated
• Fed. Circ. Revives Boehringer Diabetes Drug Patent
• Drug Wholesalers Look To Derail W.Va. Bellwether Opioid Trial
• Sacklers Say Major Purdue Deal Hinges On Longer Ch. 11 Stay
• Full Fed. Circ. Won't Let Hospira Escape $70M Epogen IP Loss
• The Biggest UK IP Cases To Watch In 2020
• 9th Circ. Says Disney Copyright Accuser Is No Godzilla
• When Coronavirus Hoarding Becomes Trade Policy
• Davis Wright Staffer's Death Not Linked To COVID-19
• Fed. Circ. Lets Stand $268M Award In Hearing Aid IP Fight
• Del. Bankruptcy Court Halts All Non-'Time-Sensitive' Hearings
• Pharmacy Groups Say Scant Facts Doom Pricing Site's Suit
• Tribunal Awaits Judge's Nod On Daiichi Drug Patent Fight
• Conn. Judge Again Finds Pradaxa Claims Preempted
• IVF Investors Want Sanctions In Chinese Hospital Fight
• Quest Can Go After Doctor In Suit Over Cancer Death
• NY County Says Meyer Suozzi Betrayed It In Opioid Case
• FDA Report Brings Hope For CBD Dietary Supplements
• 10 Ways To Continue Biz Development During Coronavirus
• BuzzFeed Sues Slew Of Federal Agencies For COVID-19 Docs
• Melinta Creditor Deal OK Clears Path To Ch. 11 Plan Approval
• Fed. Circ. Revives Jublia IP Over 'Unreasonable' Construction
• Namenda Buyers' Attys Seek $212M From Allergan Deal
• Fed. Circ. Won't Review Inherently Obvious Patent Standard
• Bankrupt Drug Co-Op Can Use Lender Cash As It Seeks Sale
• Inovio Investors Sue After COVID-19 Vaccine Claims Busted
• Wis. AG Says Drugmaker Can't 'Compartmentalize' Cert. Fight
• DC Circ. Signs Off On Serial Exclusivity For Orphan Drugs
• FTC Shouldn't Try To Protect Consumers In Foreign Countries
• Akorn Lands Final OK For $30M Deal Over Failed Merger
• 7 Ethics Considerations For Lawyers Using Lead Generators
• States' Case No Bellwether In Price-Fixing MDL, Teva Says
• US Lifts Tariffs On Chinese Medical Equipment
• 2nd Circ. Grounds Delta Flight Attendant's Sex Bias Suit
• Health Hires: Perkins Coie, Edwards Maxson, Tricida
• Eli Lilly Attys Win £400K Costs In Genentech IP Fight
• Insys Execs Say Virus Could Further Delay Surrender Dates
• Davis Wright Staffer Dies Following Flu-Like Symptoms
• Consumers Claim Diet Supplements Had Deadly Ingredients
• UK Litigation Roundup: Here's What You Missed In London
• Coronavirus: The Latest Court Closures And Restrictions
• Jury Finds CBD Co. Liable In SEC's $4M Illicit Stock Sale Suit
• Clubman Didn't Test Its Talc, VP Admits In Asbestos Trial
• China Housed 28% Of Foreign Cos. Sued By Investors In 2019
• Farmers, Monsanto Urge Dicamba Class Cert. Extension
• NY AG Tells Alex Jones To Stop Selling Fake Coronavirus Cure
• Ohio Gov., AG Unveil Opioid Settlement Framework
• CBD Co. Head Wants Conflicted Attys DQ'd In Stock Suit
• Coronavirus-Disrupted Drug Firm's $12M Ch. 11 Loan Gets OK
• SEC Relaxes Audit Verification Rules On Smaller Companies
• Pharma Group Gets $75M To Further Cancer Drug Research
• 2 Circuit Court Rulings Convolute Class Jurisdiction Outlook
• Deals Rumor Mill: Magic Leap, Tegna, WeDoctor
• Coronavirus Challenges Facing Government Contractors
• WilmerHale Steers Rare-Disease Biotech Through $75M IPO
• House Committee Advances Two VA Cannabis Bills
• Abbott Unit Wins IP Injunction On Rival's Heart Surgery Device
• Hairdressers' Exposure To Talc Went Ignored, Witness Says
• Brown Rudnick Exit Bid Challenged In $300M Malpractice Suit
• Express Scripts Can't Shake Amputee Worker's Injury Suit
• NY AG Issues Notices Targeting Purported Coronavirus Cures
• State Immunity Tops Patent Venue Rules, UT Tells Justices
• Apyx Must Face Suit Over Study Results, Judge Finds
• Marijuana Firms Say License Delay Flouts Fla. Constitution
• NJ Suspends Racing Licenses Of 7 Indicted For Horse Doping
• BASF Wants No More Delays On Dicamba Class Cert. Battle
• Humana Missed Mark On Market In Seizure Drug Suit
• NY AG Throws Support Behind Mallinckrodt $1.6B Opioid Deal
• 7th Circ. Plugs National Consumers Back Into Ill. TCPA Suit
• Juul MDL Complaints Consolidate National E-Cigarette Cases
• New Pipelines Are Needed To Close Law School Diversity Gap
• Cooley Adds Ex-Covington Pro To NY Capital Markets Team
• Chicago's Opioid Bellwether Plan Is 'Unworkable,' Judge Says
• Gilead's Ebola Drug Is Being Used To Treat COVID-19
• 21 Related Teva Price-Fixing Suits Consolidated
• Taro Escapes Off-Label Use Claims For Heart Drug
• Patent Demand Lessons For Cannabis Cos. From Big Tech
• BioPharma Outfit Raises $78.5M To Advance Cancer Therapy
• Feds Eye Tougher Oversight Of Deals Blocking Biosimilars
• Opioid Judge Taps Harvard Prof To Guide $3B Fee Fight
• Perrigo Wins Transfer Of $555M Fraud Suit To NJ
• Expert Tells NJ Jury He Found Asbestos In Clubman Talc
• Justices Urged To Allow Patents For Selective Use Of Meds
• 'Compound King' Convicted In $21M Health Care Fraud Case
• Covidien, Ethicon Revisit IP Rivalry As Device Trial Closes
• Fired NJ Medical Pot User Can Sue Over Disability Bias
• Fed. Circ. Rejects Challenge To 2010 USPTO Patent Term Rule
• Vape Makers Take FDA Challenge To DC Circ.
• BASF, Dow Can't Escape Polyurethane Price-Fixing MDL
• Lessons Learned From Remicade Biosimilar Patent Row
• JLL Partners Joins Medical Industry Veteran In $100M JV
• How To Search For A Transformational Law Firm COO
• Pa. Had No Role In Out-Of-State Mesh Case, Justices Told
• Coronavirus Derails Eagerly Awaited New York Opioid Trial
• Allen & Overy Assists On $600M European Life Sciences Fund
• CMA Sent Back To The Drawing Board In £89M Pfizer Case
• 4 Ethics Tips For Lawyers As Coronavirus Spreads
• 3rd Circ. Signals Disapproval Of Lamictal Antitrust Class Cert.
• Market Turbulence Throws IPO Pipeline Into Question
• Patent Trial Opens Over DNA Tool Used To ID Coronavirus
• ITC To Probe Alleged Infringement Of Nicotine Pouch Patent
• Calif. Appeals Court Upholds Local Ban On Pot Dispensary
• Over 2 Dozen Charged In Alleged Racehorse Doping Schemes
• Surescripts Wants DC Circ. To Review FTC Antitrust Suit
• Judge OKs Par's Settlement In Zetia Pay-For-Delay Case
• Mylan Says Generic Drugs Can't Override IP Venue Law
• FDA Hits Vitamin Co., Televangelist For Fake COVID-19 Cures
• 1-800 Contacts Disputes FTC Found 'Take It Or Leave It' Deals
• FDA Defends Approval Of Genetically Engineered Salmon
• United Opens New Front In Celgene Monopoly Fight
• Top Blockchain Considerations For Health, Life Sciences Cos.
• Keep Your Client Out Of The Courtroom During Voir Dire
• Drug Researcher Charles River Sued For Hiring Activist Spy
• Muscle Milk Maker Reaches $12M Deal To End False Ad Suit
• SEC Says Priest In Fraud Case Threatened Potential Witness
• Curaleaf Looks To Permanently End Investors' Stock-Drop Suit
• 7th Circ. Won't Reinstate $3M Verdict For Reed Smith Widow
• Germ-X Maker Sued Over Coronavirus Protection Claims
• Fed. Circ. Weighs Undoing $268M Verdict Against Cochlear
• Doctors Say No Secret Info Used In FCA Suit Against J&J
• Pot Co. Tilray Hit With Securities Suit After $321M Net Loss
• Asset Mgr. Piles Onto Perrigo Price-Fixing, Securities Claims
• Fed. Circ. Affirms PTAB Save Of Dartmouth Patent Claim
• Assertio, Lupin, Bausch Must Face Buyers' Price-Fixing Suit
• Fed. Circ. Won't Block Amgen's Herceptin Biosimilar
• Winston & Strawn, Loeb & Loeb Steer 2 IPOs Worth $660M
• Cannabis Bill Roundup: Connecticut Talks Legalization
• Suboxone Buyers Fight 3rd Circ. Appeal Of Class Cert.
• Coronavirus-Impacted Drug Firm Gets OK On Ch. 11 Sale Plan
• FDA Focus: What King & Spalding's Practice Head Is Watching
• A Possible Limit On High Court 2005 Agency Deference Ruling
• AARP, Consumer Groups Back Calif. Pay-For-Delay Ban
• Proactiv Producer Says Pharmacies Faked Reimbursements
• J&J Escapes Suit After Couple Can't ID Pelvic Mesh Maker
• Investor Sues Biopharma Co. Over Study Disclosure
• Justices Reverse Alito's Partial Stay Of Generics Discovery
• Steps For Cos. Reacting To Anonymous Short-Seller Claims
• It Can Be Risky For Litigators To Advise On Litigation Funding
• Illinois Brick Doesn't Kill Med Supply Suit, 7th Circ. Says
• Pharma Investor Says $11M Public Offering Breached Contract
• 1-800 Contacts Tells 2nd Circ. FTC Wrongly Barred Ad Deals
• ABA, Health Tech Events Scuttled Amid Coronavirus Fears
• Fed. Circ. Grapples With Double-Patenting In Enbrel Case
• Noncompete Can't Kill Radiology Salesman's Jump To Startup
• Fed. Circ. Doubts Illegality Of USPTO's 2010 Patent Term Rule
• Purdue Wants Ch. 11 To Hold Opioid Cases At Bay Longer
• Fed. Circ. Affirms Celltrion, Hospira Didn't Infringe Janssen IP
• Del. Justices To Weigh In On AmerisourceBergen Doc Fight
• DOJ Urges High Court Not To Eye FCA Dismissal Campaign
• New Jersey Jury Told That Barbershop Talc Caused Cancer
• Feds Say Spine Device Firm Ran $8M Kickback Scam
• 2 Firms Edge Ahead Of Peers In Quiet February For IPOs
• Fed. Prohibition Trumps State Med. Marijuana Law, Utility Says
• Insys Execs Can't Delay Prison In Opioid Kickback Case
• Stop Asking Bar Applicants About Mental Illness
• 3rd. Circ. Doubts Lawsuit Press Release Defamed Pharma Co.
• Celgene Tells Justices Retroactive IPRs Are Unconstitutional
• Anika Therapeutics Hires Insulet, Covidien Alum As GC
• Fed. Circ. Asks If All J&J Units Belong In Remicade IP Fight
• House Greenlights $8.3B For Fighting Coronavirus
• Gilead Can't Duck Sweeping Competition Suit Over HIV Drugs
• 9th Circ. Says Judge Wrongly Put Warning In FDA Complaint
• Fed. Circ. Affirms Automated Eye Exam IP Wasn't Infringed
• Vaccine IP Under Microscope With Coronavirus Outbreak
• Ex-NFL Player Must Undergo Psych Evals In Pain Pump Case
• New York Court Refuses To Delay March Opioid Trial
• Loeb & Loeb Picks Up DLA Piper FDA Team Head In DC
• Topical Cream Maker Fights Dismissal Of CBD Product Suit
• High Court Must Reject Unconstitutional La. Abortion Law
• Gov't Intervention In A Private Civil Suit Can Benefit Defendant
• Teva Wants 'Scattershot' 401(k) Fee Suit Scrapped
• What The Coronavirus Means For Arbitration And Mediation
• NeuroMetrix Settles FTC Suit Over Wearable Devices For $4M
• Fed. Circ. Calls Biotech's Last-Minute Bid An 'Ambush'
• Feds Claim Pharmacists Ran Protein Shake Kickback Scheme
• Enzo Tells Justices Fed. Circ. Set 'Lax' New Enablement Test
• Rival Dental Supplier Slams 2nd Arbitration Bid At High Court
• Cannabis IP Expert Joins Panitch Schwarze
• Tech Developer Says Wage Suit With Pot Co. Belongs in Calif.
• Feds Tell High Court ERISA Doesn't Doom Arkansas PBM Law
• Venture-Backed Imara Primes $76M IPO Amid Volatile Market
• Tracing The Fate Of The Decade's Biggest Patent Verdicts
• Canadian Pot Cos. Settle Joint Venture Ownership Dispute
• Gov't Attys' Conduct In Medical Co. Kickback Suit Deemed OK
• What Congress Misses About Universal Injunctions
• Why I Became A Lawyer: Lessons From 'Italian Summer Camp'
• Foreign Influence Lessons From Research Org FCA Deal
• DOJ Says Mallinckrodt Bilked Medicaid As Drug Price Soared
• Biggest Patent Verdicts Fall To Fed. Circ.'s Ever-Moving Target
• Gunderson Dettmer Reps Hearing Loss Co. On $105M Funding
• CBD Firm Head Says Co. Must Cover Her Stock Suit Defense
• 6 Firms Drive Thermo Fisher's $11.5B Deal For Qiagen
• Investors Say Shire Tried To Spin Free Of $45M Merger Tab
• Pharmacies Say Surescripts Can't Duck Monopolization Suit
• Bayer, Google Among Cos. Urging Change To Expert Standard
• Boston Scientific Blasts $5.5M Atty Fee Award In FCA Suit
• Church & Dwight Must Face False Ad Suit Over Vitamins
• Mass. Judge Refuses To Ban CPAP Cleaner From Expo
• Fed. Circ. Judge Considers Retrying Alere Drug-Test IP Fight
• Rosen Firm Wants To Lead Investor Suits Against Fla. Pot Co.
• USPTO Signals It's Eyeing High Court For Arthrex Progeny
• 46 AGs Back Arkansas In High Court ERISA Preemption Fight
• Ex-USPTO Chief's Testimony Not A 'Waste Of Time,' Court Told
• White & Case Guides $825M Takeda Drug Divestment
• US Chamber Urges Justices To Hear Generics Discovery Issue
• Workers Say Yale's Wellness Policy Violates Bias Laws
• NY Cancer Doc Dodges Prison In Insys Kickbacks Case
• Prepare Your Law Firm Tech For Coronavirus Impact
• Mediators To Form Plan For Purdue Ch. 11 Claims Distribution
• 5th Circ. Clears Walgreens In Amputee's Storefront Crash Suit
• Harsher Terms Nixed For Cases Tainted By Mass. Lab Scandal
• Puma Biotech Can't Upend $22M Loss In Exec's Libel Case
• Atty Tips To Avoid 'Scope Creep' And Malpractice Claims
• Commerce Sets Preliminary Duties On Plastic Sheets
• Goodwin-Steered Akrevia Rebrands, Nabs $100.5M Funding
• Sandoz To Pay $195M For Generic-Drug Antitrust Violations
• Shook Hardy Brings On 4 Goodell DeVries Attys In Philly
• Diagnosing Sales Tax Rules for Digital Health Products
• Hetero, Zydus Settle Novartis MS Drug Suits Before IP Trial
• PharMerica FCA Decision Is A Win For Statutory Interpretation
• AGs Claim Ample Evidence In Generic Drug Price-Fixing Suit
• GSK Settles Anemia Drug Patent Claims On Eve Of Trial
• Slaughter And May Steers Life Science Co.'s $130M Financing
• Medical Device Maker Wants Asset Case Tossed From Philly
• 'Precision Medicine' Raises Complex Legal And Ethical Issues
• Navigating Uncertainty In Digital Health Patent Eligibility
• Skadden, Cooley Guide $4.9B Deal For Cancer Drugmaker